Sugi Predict

Sugi Predict / Compounds / SCHEMBL1675466

SCHEMBL1675466

SCHEMBL1675466

O=C(O)c1cccc(-c2nc3ccccc3o2)c1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HPSE Q9Y251 3/20 0.64
▸ DUSP1 P28562 1/20 0.60
▸ MAPT P10636 3/20 0.58
▸ MEN1 O00255 2/20 0.58
▸ KMT2A Q03164 2/20 0.58
▸ KDM4E B2RXH2 6/20 0.57
▸ SMN1; SMN2 Q16637 3/20 0.57
▸ POLB P06746 2/20 0.57
▸ HSD17B10 Q99714 5/20 0.56
▸ TP53 P04637 2/20 0.56
▸ USP2 O75604 2/20 0.56
▸ ALDH1A1 P00352 3/20 0.53
▸ HPGD P15428 2/20 0.53
▸ TTR P02766 1/20 0.53
▸ ALB P02768 1/20 0.53
▸ MAOA P21397 1/20 0.53
▸ CNR1 P21554 1/20 0.53
▸ DRD1 P21728 1/20 0.53
▸ OPRD1 P41143 1/20 0.53
▸ PDE4D Q08499 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1675377 0.88 TTR (0.68) HPSEDUSP1MAPTMEN1KMT2A
SCHEMBL1675525 0.88 HDAC6 (0.63) HPSEMAPTMEN1KMT2AKDM4E
SCHEMBL1675473 0.87 HPSE (0.66) HPSEKDM4ESMN1; SMN2POLBALDH1A1
SCHEMBL1675639 0.87 TTR (0.56) HPSEDUSP1MAPTMEN1KMT2A
SCHEMBL11371944 0.87 MAPT (0.57) HPSEDUSP1MAPTMEN1KMT2A
SCHEMBL28266926 0.87 KDM4E (0.62) DUSP1MAPTMEN1KMT2AKDM4E
SCHEMBL2855757 0.87 MAPT (0.57) HPSEDUSP1MAPTMEN1KMT2A
Benzoic Acid SCHEMBL11551976 0.85 NPC1 (0.68) HPSEMAPTMEN1KMT2AKDM4E
SCHEMBL31472973 0.85 HDAC6 (0.70) DUSP1MAPTKDM4ESMN1; SMN2POLB
SCHEMBL28605747 0.85 HDAC6 (0.70) DUSP1MAPTKDM4ESMN1; SMN2POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 92 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140135305-A1 METHODS FOR TREATING SPINAL MUSCULAR ATROPHY PTC THERAPEUTICS, INC. (US) 2014-05-15 — — US claimed
US-20110086833-A1 METHODS FOR TREATING SPINAL MUSCULAR ATROPHY PTC THERAPEUTICS, INC. 2011-04-14 — — US claimed
WO-2009151546-A2 METHODS FOR TREATING SPINAL MUSCULAR ATROPHY PTC THERAPEUTICS, INC. (US) 2009-12-17 — — WO claimed
US-20260076962-A1 LANTHIONINE SYNTHETASE C-LIKE 2-BASED THERAPEUTICS NIMMUNE BIOPHARMA, INC. (US) 2026-03-19 — — US disclosed
US-12502388-B2 Lanthionine synthetase C-like 2-based therapeutics NIMMUNE BIOPHARMA, INC. (US) 2025-12-23 — — US disclosed
US-20230142910-A1 LANTHIONINE SYNTHETASE C-LIKE 2-BASED THERAPEUTICS LANDOS BIOPHARMA, INC. (US) 2023-05-11 — — US disclosed
US-20230142910-A1 LANTHIONINE SYNTHETASE C-LIKE 2-BASED THERAPEUTICS LANDOS BIOPHARMA, INC. (US) 2023-05-11 — — US disclosed
US-11571419-B2 Lanthionine synthetase C-like 2-based therapeutics LANDOS BIOPHARMA, INC. (US) 2023-02-07 — — US disclosed
US-11571419-B2 Lanthionine synthetase C-like 2-based therapeutics LANDOS BIOPHARMA, INC. (US) 2023-02-07 — — US disclosed
EP-3757099-B1 LANTHIONINE SYNTHETASE C-LIKE 2-BASED THERAPEUTICS LANDOS BIOPHARMA INC (US) 2022-06-01 — — EP disclosed
EP-3757099-B1 LANTHIONINE SYNTHETASE C-LIKE 2-BASED THERAPEUTICS LANDOS BIOPHARMA INC (US) 2022-06-01 — — EP disclosed
CN-1740169-A Arylmethylamine derivatives for use as tryptase inhibitors AVENTIS PHARMA INC (US) 2006-03-01 — — CN disclosed
US-6977263-B2 Chemical compounds AVENTIS PHARMACEUTICALS INC. (US) 2005-12-20 — — US disclosed
CN-1230431-C Arylmethylamine derivatives useful as tryptase inhibitors AVENTIS PHARM PROD INC (US) 2005-12-07 — — CN disclosed
US-20050228018-A1 Chemical compounds AVENTIS PHARMACEUTICALS INC. (US) 2005-10-13 — — US disclosed
US-20030187020-A1 Chemical compounds AVENTISUB LLC 2003-10-02 — — US disclosed
CN-1439003-A Arylmethylamine derivatives useful as tryptase inhibitors AVENTIS PHARM PROD INC (US) 2003-08-27 — — CN disclosed
EP-1296972-A1 ARYLMETHYLAMINE DERIVATIVES FOR USE AS TRYPTASE INHIBITORS Aventis Pharmaceuticals Inc. (US) 2003-04-02 — — EP disclosed
WO-2001090101-A1 ARYLMETHYLAMINE DERIVATIVES FOR USE AS TRYPTASE INHIBITORS AVENTIS PHARMACEUTICALS INC. (US) 2001-11-29 — — WO disclosed
US-4659360-A HERBICIDES FMC CORPORATION (US) 1987-04-21 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110086833-A1 METHODS FOR TREATING SPINAL MUSCULAR ATROPHY SMN1; SMN2, NSUN2, SNRPB2 HPSE 2578/4885DUSP1 4742/4885MAPT 775/4885
US-12502388-B2 Lanthionine synthetase C-like 2-based therapeutics LANCL2, CBS, LCP2 HPSE 2554/4885DUSP1 2411/4885MAPT 3162/4885
US-11571419-B2 Lanthionine synthetase C-like 2-based therapeutics LANCL2, CBS, LCP2 HPSE 2554/4885DUSP1 2411/4885MAPT 3162/4885
US-20050228018-A1 Chemical compounds CMA1, TPSB2, TPSG1 HPSE 331/4885DUSP1 4195/4885MAPT 1376/4885
US-20260076962-A1 LANTHIONINE SYNTHETASE C-LIKE 2-BASED THERAPEUTICS SCLY, CLCN2, CBS HPSE 4055/4885DUSP1 1404/4885MAPT 4651/4885
US-20030187020-A1 Chemical compounds CMA1, TPSB2, TPSG1 HPSE 331/4885DUSP1 4195/4885MAPT 1376/4885
US-20140135305-A1 METHODS FOR TREATING SPINAL MUSCULAR ATROPHY SMN1; SMN2, NSUN2, SNRPB2 HPSE 2578/4885DUSP1 4742/4885MAPT 775/4885
US-20230142910-A1 LANTHIONINE SYNTHETASE C-LIKE 2-BASED THERAPEUTICS LANCL2, CBS, LCP2 HPSE 2554/4885DUSP1 2411/4885MAPT 3162/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.